Center of Drug Metabolism and Pharmacokinetics, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, China.
Acta Pharmacol Sin. 2024 Jul;45(7):1406-1424. doi: 10.1038/s41401-024-01251-6. Epub 2024 Apr 8.
Acute kidney injury (AKI) is often accompanied by uremic encephalopathy resulting from accumulation of uremic toxins in brain possibly due to impaired blood-brain barrier (BBB) function. Anionic uremic toxins are substrates or inhibitors of organic anionic transporters (OATs). In this study we investigated the CNS behaviors and expression/function of BBB OAT3 in AKI rats and mice, which received intraperitoneal injection of cisplatin 8 and 20 mg/kg, respectively. We showed that cisplatin treatment significantly inhibited the expressions of OAT3, synaptophysin and microtubule-associated protein 2 (MAP2), impaired locomotor and exploration activities, and increased accumulation of uremic toxins in the brain of AKI rats and mice. In vitro studies showed that uremic toxins neither alter OAT3 expression in human cerebral microvascular endothelial cells, nor synaptophysin and MAP2 expressions in human neuroblastoma (SH-SY5Y) cells. In contrast, tumour necrosis factor alpha (TNFα) and the conditioned medium (CM) from RAW264.7 cells treated with indoxyl sulfate (IS) significantly impaired OAT3 expression. TNFα and CM from IS-treated BV-2 cells also inhibited synaptophysin and MAP2 expressions in SH-SY5Y cells. The alterations caused by TNFα and CMs in vitro, and by AKI and TNFα in vivo were abolished by infliximab, a monoclonal antibody designed to intercept and neutralize TNFα, suggesting that AKI impaired the expressions of OAT3, synaptophysin and MAP2 in the brain via IS-induced TNFα release from macrophages or microglia (termed as IS-TNFα axis). Treatment of mice with TNFα (0.5 mg·kg·d, i.p. for 3 days) significantly increased p-p65 expression and reduced the expressions of Nrf2 and HO-1. Inhibiting NF-κB pathway, silencing p65, or activating Nrf2 and HO-1 obviously attenuated TNFα-induced downregulation of OAT3, synaptophysin and MAP2 expressions. Significantly increased p-p65 and decreased Nrf2 and HO-1 protein levels were also detected in brain of AKI mice and rats. We conclude that AKI inhibits the expressions of OAT3, synaptophysin and MAP2 due to IS-induced TNFα release from macrophages or microglia. TNFα impairs the expressions of OAT3, synaptophysin and MAP2 partly via activating NF-κB pathway and inhibiting Nrf2-HO-1 pathway.
急性肾损伤 (AKI) 常伴有尿毒症脑病,这可能是由于尿毒症毒素在大脑中蓄积,损害血脑屏障 (BBB) 功能所致。阴离子尿毒症毒素是有机阴离子转运体 (OAT) 的底物或抑制剂。在这项研究中,我们研究了 AKI 大鼠和小鼠腹膜内注射顺铂 8 和 20mg/kg 后中枢神经系统行为和 BBB OAT3 的表达/功能。我们发现顺铂治疗显著抑制了 OAT3、突触小体和微管相关蛋白 2 (MAP2) 的表达,损害了 AKI 大鼠和小鼠的运动和探索活动,并增加了尿毒症毒素在大脑中的蓄积。体外研究表明,尿毒症毒素既不改变人脑血管内皮细胞中 OAT3 的表达,也不改变人神经母细胞瘤 (SH-SY5Y) 细胞中突触小体和 MAP2 的表达。相反,肿瘤坏死因子-α (TNFα) 和用靛玉红硫酸盐 (IS) 处理的 RAW264.7 细胞的条件培养基 (CM) 显著抑制 OAT3 的表达。IS 处理的 BV-2 细胞的 TNFα 和 CM 也抑制了 SH-SY5Y 细胞中突触小体和 MAP2 的表达。体内 AKI 和 TNFα 以及体外 TNFα 和 CM 引起的改变,通过阻断和中和 TNFα 的单克隆抗体 infliximab 被消除,这表明 AKI 通过 IS 诱导的巨噬细胞或小胶质细胞中 TNFα 的释放 (称为 IS-TNFα 轴) 损害了大脑中 OAT3、突触小体和 MAP2 的表达。用 TNFα(0.5mg·kg·d,腹膜内注射,连续 3 天)处理小鼠可显著增加 p-p65 的表达,降低 Nrf2 和 HO-1 的表达。抑制 NF-κB 通路、沉默 p65 或激活 Nrf2 和 HO-1 可明显减弱 TNFα 诱导的 OAT3、突触小体和 MAP2 表达下调。在 AKI 小鼠和大鼠的大脑中也检测到明显增加的 p-p65 和减少的 Nrf2 和 HO-1 蛋白水平。我们得出结论,AKI 抑制了 OAT3、突触小体和 MAP2 的表达,这是由于 IS 诱导的巨噬细胞或小胶质细胞中 TNFα 的释放。TNFα 通过激活 NF-κB 通路和抑制 Nrf2-HO-1 通路部分损害了 OAT3、突触小体和 MAP2 的表达。